Certain Warrants of Onconova Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2021.
December 22, 2021
Share
Certain Warrants of Onconova Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2021. These Warrants will be under lockup for 91 days starting from 23-SEP-2021 to 23-DEC-2021.
Details:
The company's stockholders and our directors and executive officers have agreed with the underwriters that, subject to certain customary exceptions, without the prior written consent of Guggenheim Securities, LLC on behalf of the underwriters, they will not, for the Lock-Up Period i.e. 90 days after the date of the prospectus, directly or indirectly, (a) offer, pledge, sell, contract to sell, solicit offers to purchase, grant any call option or purchase any put option with respect to, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock.
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclibâs mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).